HEADER TRANSCRIPTION 03-DEC-18 6Q2W TITLE CRYSTAL STRUCTURE OF HUMAN ROR GAMMA LBD IN COMPLEX WITH A QUINOLINE TITLE 2 SULFONAMIDE INVERSE AGONIST COMPND MOL_ID: 1; COMPND 2 MOLECULE: NUCLEAR RECEPTOR ROR-GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: NUCLEAR RECEPTOR RZR-GAMMA,NUCLEAR RECEPTOR SUBFAMILY 1 COMPND 5 GROUP F MEMBER 3,RAR-RELATED ORPHAN RECEPTOR C,RETINOID-RELATED COMPND 6 ORPHAN RECEPTOR-GAMMA; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: RORC, NR1F3, RORG, RZRG; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS ROR GAMMA, INVERSE AGONIST, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR F.CIESIELSKI,J.AMAUDRUT,M.A.ARGIRIADI,M.BARTH,E.C.BREINLINGER, AUTHOR 2 D.J.CALDERWOOD,K.P.CUSACK,M.E.KORT,C.MONTALBETTI,D.POTIN, AUTHOR 3 O.POUPARDIN,L.SPITZER REVDAT 3 24-JAN-24 6Q2W 1 REMARK REVDAT 2 12-JUN-19 6Q2W 1 AUTHOR JRNL REVDAT 1 29-MAY-19 6Q2W 0 JRNL AUTH J.AMAUDRUT,M.A.ARGIRIADI,M.BARTH,E.C.BREINLINGER,D.BRESSAC, JRNL AUTH 2 P.BROQUA,D.J.CALDERWOOD,M.CHATAR,K.P.CUSACK,S.B.GAULD, JRNL AUTH 3 S.JACQUET,R.V.KAMATH,M.E.KORT,V.LEPAIS,J.M.LUCCARINI, JRNL AUTH 4 P.MASSON,C.MONTALBETTI,L.MOUNIER,D.POTIN,O.POUPARDIN, JRNL AUTH 5 S.ROUAUD,L.SPITZER,C.D.WALLACE JRNL TITL DISCOVERY OF NOVEL QUINOLINE SULPHONAMIDE DERIVATIVES AS JRNL TITL 2 POTENT, SELECTIVE AND ORALLY ACTIVE ROR GAMMA INVERSE JRNL TITL 3 AGONISTS. JRNL REF BIOORG.MED.CHEM.LETT. V. 29 1799 2019 JRNL REFN ESSN 1464-3405 JRNL PMID 31101472 JRNL DOI 10.1016/J.BMCL.2019.05.015 REMARK 2 REMARK 2 RESOLUTION. 1.99 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.99 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 46.20 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 3 NUMBER OF REFLECTIONS : 30868 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.190 REMARK 3 R VALUE (WORKING SET) : 0.187 REMARK 3 FREE R VALUE : 0.232 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1625 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3569 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 82 REMARK 3 SOLVENT ATOMS : 173 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 36.17 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 39.93 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -3.94000 REMARK 3 B22 (A**2) : -1.81000 REMARK 3 B33 (A**2) : 2.83000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.10000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.189 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.166 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.145 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 5.533 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS U VALUES : REFINED INDIVIDUALLY REMARK 4 REMARK 4 6Q2W COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 03-DEC-18. REMARK 100 THE DEPOSITION ID IS D_1200013214. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-MAR-12 REMARK 200 TEMPERATURE (KELVIN) : 77 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SOLEIL REMARK 200 BEAMLINE : PROXIMA 1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.981 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 32496 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.990 REMARK 200 RESOLUTION RANGE LOW (A) : 46.200 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 200 DATA REDUNDANCY : 3.678 REMARK 200 R MERGE (I) : 0.07700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 10.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.99 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.11 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.4 REMARK 200 DATA REDUNDANCY IN SHELL : 3.45 REMARK 200 R MERGE FOR SHELL (I) : 0.32600 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.630 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER 2.8.2 REMARK 200 STARTING MODEL: 3B0W REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.55 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.30 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1M MGCL2, 0.1M MES PH 6, 8% W/V PEG REMARK 280 6000, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 63.56000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 28.10000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 63.56000 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 28.10000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLN B 487 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LEU A 267 CG CD1 CD2 REMARK 470 THR A 268 OG1 CG2 REMARK 470 GLU A 269 CG CD OE1 OE2 REMARK 470 GLU A 271 CG CD OE1 OE2 REMARK 470 GLN A 487 CG CD OE1 NE2 REMARK 470 GLU B 269 CG CD OE1 OE2 REMARK 470 GLU B 271 CG CD OE1 OE2 REMARK 470 HIS B 272 CG ND1 CD2 CE1 NE2 REMARK 470 LYS B 469 CG CD CE NZ REMARK 470 ARG B 473 CG CD NE CZ NH1 NH2 REMARK 470 GLN B 484 CG CD OE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 268 -68.34 15.59 REMARK 500 GLU A 435 62.14 -117.65 REMARK 500 GLU B 435 64.24 -103.59 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue HBW A 1001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue HBW B 1001 DBREF 6Q2W A 267 487 UNP P51449 RORG_HUMAN 267 487 DBREF 6Q2W B 267 487 UNP P51449 RORG_HUMAN 267 487 SEQRES 1 A 221 LEU THR GLU ILE GLU HIS LEU VAL GLN SER VAL CYS LYS SEQRES 2 A 221 SER TYR ARG GLU THR CYS GLN LEU ARG LEU GLU ASP LEU SEQRES 3 A 221 LEU ARG GLN ARG SER ASN ILE PHE SER ARG GLU GLU VAL SEQRES 4 A 221 THR GLY TYR GLN ARG LYS SER MET TRP GLU MET TRP GLU SEQRES 5 A 221 ARG CYS ALA HIS HIS LEU THR GLU ALA ILE GLN TYR VAL SEQRES 6 A 221 VAL GLU PHE ALA LYS ARG LEU SER GLY PHE MET GLU LEU SEQRES 7 A 221 CYS GLN ASN ASP GLN ILE VAL LEU LEU LYS ALA GLY ALA SEQRES 8 A 221 MET GLU VAL VAL LEU VAL ARG MET CYS ARG ALA TYR ASN SEQRES 9 A 221 ALA ASP ASN ARG THR VAL PHE PHE GLU GLY LYS TYR GLY SEQRES 10 A 221 GLY MET GLU LEU PHE ARG ALA LEU GLY CYS SER GLU LEU SEQRES 11 A 221 ILE SER SER ILE PHE ASP PHE SER HIS SER LEU SER ALA SEQRES 12 A 221 LEU HIS PHE SER GLU ASP GLU ILE ALA LEU TYR THR ALA SEQRES 13 A 221 LEU VAL LEU ILE ASN ALA HIS ARG PRO GLY LEU GLN GLU SEQRES 14 A 221 LYS ARG LYS VAL GLU GLN LEU GLN TYR ASN LEU GLU LEU SEQRES 15 A 221 ALA PHE HIS HIS HIS LEU CYS LYS THR HIS ARG GLN SER SEQRES 16 A 221 ILE LEU ALA LYS LEU PRO PRO LYS GLY LYS LEU ARG SER SEQRES 17 A 221 LEU CYS SER GLN HIS VAL GLU ARG LEU GLN ILE PHE GLN SEQRES 1 B 221 LEU THR GLU ILE GLU HIS LEU VAL GLN SER VAL CYS LYS SEQRES 2 B 221 SER TYR ARG GLU THR CYS GLN LEU ARG LEU GLU ASP LEU SEQRES 3 B 221 LEU ARG GLN ARG SER ASN ILE PHE SER ARG GLU GLU VAL SEQRES 4 B 221 THR GLY TYR GLN ARG LYS SER MET TRP GLU MET TRP GLU SEQRES 5 B 221 ARG CYS ALA HIS HIS LEU THR GLU ALA ILE GLN TYR VAL SEQRES 6 B 221 VAL GLU PHE ALA LYS ARG LEU SER GLY PHE MET GLU LEU SEQRES 7 B 221 CYS GLN ASN ASP GLN ILE VAL LEU LEU LYS ALA GLY ALA SEQRES 8 B 221 MET GLU VAL VAL LEU VAL ARG MET CYS ARG ALA TYR ASN SEQRES 9 B 221 ALA ASP ASN ARG THR VAL PHE PHE GLU GLY LYS TYR GLY SEQRES 10 B 221 GLY MET GLU LEU PHE ARG ALA LEU GLY CYS SER GLU LEU SEQRES 11 B 221 ILE SER SER ILE PHE ASP PHE SER HIS SER LEU SER ALA SEQRES 12 B 221 LEU HIS PHE SER GLU ASP GLU ILE ALA LEU TYR THR ALA SEQRES 13 B 221 LEU VAL LEU ILE ASN ALA HIS ARG PRO GLY LEU GLN GLU SEQRES 14 B 221 LYS ARG LYS VAL GLU GLN LEU GLN TYR ASN LEU GLU LEU SEQRES 15 B 221 ALA PHE HIS HIS HIS LEU CYS LYS THR HIS ARG GLN SER SEQRES 16 B 221 ILE LEU ALA LYS LEU PRO PRO LYS GLY LYS LEU ARG SER SEQRES 17 B 221 LEU CYS SER GLN HIS VAL GLU ARG LEU GLN ILE PHE GLN HET HBW A1001 41 HET HBW B1001 41 HETNAM HBW (2~{S})-1-[2,4-BIS(CHLORANYL)-3-[[4-IMIDAZOL-1-YL-2- HETNAM 2 HBW (TRIFLUOROMETHYL)QUINOLIN-8- HETNAM 3 HBW YL]OXYMETHYL]PHENYL]SULFONYL-~{N}-METHYL-PYRROLIDINE- HETNAM 4 HBW 2-CARBOXAMIDE FORMUL 3 HBW 2(C26 H22 CL2 F3 N5 O4 S) FORMUL 5 HOH *173(H2 O) HELIX 1 AA1 THR A 268 GLU A 283 1 16 HELIX 2 AA2 ARG A 288 GLN A 295 1 8 HELIX 3 AA3 ARG A 296 ASN A 298 5 3 HELIX 4 AA4 SER A 301 ARG A 310 1 10 HELIX 5 AA5 SER A 312 LEU A 338 1 27 HELIX 6 AA6 GLY A 340 LEU A 344 5 5 HELIX 7 AA7 CYS A 345 CYS A 366 1 22 HELIX 8 AA8 GLY A 384 GLY A 392 5 9 HELIX 9 AA9 CYS A 393 ALA A 409 1 17 HELIX 10 AB1 SER A 413 ILE A 426 1 14 HELIX 11 AB2 GLU A 435 HIS A 458 1 24 HELIX 12 AB3 ARG A 459 LEU A 466 5 8 HELIX 13 AB4 PRO A 468 GLN A 478 1 11 HELIX 14 AB5 HIS A 479 GLN A 484 1 6 HELIX 15 AB6 THR B 268 CYS B 285 1 18 HELIX 16 AB7 ARG B 288 GLN B 295 1 8 HELIX 17 AB8 ARG B 296 ASN B 298 5 3 HELIX 18 AB9 SER B 301 ARG B 310 1 10 HELIX 19 AC1 SER B 312 ARG B 337 1 26 HELIX 20 AC2 CYS B 345 MET B 365 1 21 HELIX 21 AC3 GLY B 384 GLY B 392 5 9 HELIX 22 AC4 CYS B 393 ALA B 409 1 17 HELIX 23 AC5 SER B 413 ILE B 426 1 14 HELIX 24 AC6 GLU B 435 THR B 457 1 23 HELIX 25 AC7 ARG B 459 LEU B 466 5 8 HELIX 26 AC8 PRO B 468 SER B 477 1 10 HELIX 27 AC9 HIS B 479 GLN B 484 1 6 SHEET 1 AA1 3 TYR A 369 ASN A 370 0 SHEET 2 AA1 3 THR A 375 PHE A 378 -1 O THR A 375 N ASN A 370 SHEET 3 AA1 3 LYS A 381 GLY A 383 -1 O LYS A 381 N PHE A 378 SHEET 1 AA2 3 TYR B 369 ASN B 370 0 SHEET 2 AA2 3 THR B 375 PHE B 378 -1 O THR B 375 N ASN B 370 SHEET 3 AA2 3 LYS B 381 GLY B 383 -1 O LYS B 381 N PHE B 378 SITE 1 AC1 18 GLN A 286 LEU A 287 HIS A 323 MET A 358 SITE 2 AC1 18 VAL A 361 LEU A 362 MET A 365 ALA A 368 SITE 3 AC1 18 PHE A 377 PHE A 378 PHE A 388 LEU A 475 SITE 4 AC1 18 CYS A 476 GLN A 478 HIS A 479 VAL A 480 SITE 5 AC1 18 HOH A1118 HOH A1143 SITE 1 AC2 17 GLN B 286 HIS B 323 LEU B 324 MET B 358 SITE 2 AC2 17 VAL B 361 LEU B 362 MET B 365 PHE B 377 SITE 3 AC2 17 PHE B 378 PHE B 388 LEU B 475 CYS B 476 SITE 4 AC2 17 GLN B 478 HIS B 479 VAL B 480 HOH B1141 SITE 5 AC2 17 HOH B1156 CRYST1 127.120 56.200 81.400 90.00 125.06 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007867 0.000000 0.005521 0.00000 SCALE2 0.000000 0.017794 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015008 0.00000